業績(論文)

順天堂大学救急・災害医学

PUBLICATIONS in 2015

  1. Liaw P, Ito T, Iba T, Thachil J, Zeerleder S. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Reviews 2015 doi: 10.1016/j.blre.2015.12.004
  2. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a Japanese perspective. International Journal of hematology 2015; Nov 20.
  3. Iba T, Ito T, Maruyama I, Jilma B, Brenner T, Müller MCA, Juffermans NP, Thachil J. Potential diagnostic markers for disseminated intravascular coagulation of sepsis. Blood Reviews 2015 doi: 10.1016/j.blre.2015.10.002.
  4. Palungwachira P, Bundit C, Vatcharothayangul C, Churproong S, Sumi Y, Yanagawa Y, Iba T, Tanaka H. Clinical Elective Study Report at the Department of Emergency and Critical Care Medicine in Juntendo University Faculty of Medicine. Juntendo Medical Journal 2015;61(2):166-70.
  5. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Kadota K, Sato K. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp 2015;3(1):36.
  6. Yuri M, Tabe Y, Tsuchiya K, Sadatsuki R, Aoki J, Horii T, Iba T, Ohsaka A. Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Clin Appl Thromb Hemost 2015 pii: 1076029615595878.
  7. Miki T, Iba T. Kinetics of Circulating Damage-Associated Molecular Patterns in Sepsis. J Immunol Res 2015:424575.
  8. Iba T, Nagakari K. The effect of plasma-derived activated protein C on leukocyte cell-death and vascular endothelial damage. Thromb Res 2015;135(5):963-9.
  9. Iba T, Saitoh D, Gando S, Thachil J. The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res 2015;135(5):897-901.
  10. Iba T. Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation. Crit Care 2015;19:233.
  11. Iba T. Controversies regarding the use of antithrombin for sepsis-associated disseminated intravascular coagulation: an update of the evidence. Blood Transfus 2015;13(1):166
  12. Iba T. Antithrombin or thrombomodulin administration in severe pneumonia patients with sepsis and disseminated intravascular coagulation: comment on two papers. J Thromb Haemost 2015;13:682-3

PUBLICATIONS in 2014

  1. Iba T, Saitoh D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Critical Care 2014; 18(5): 497
  2. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin modulates neutorophil cell-death and decreases circulating DAMPs levels in endotoxemic rats. Thromb Res 2014; 134(1): 169-173.
  3. Iba T, Aihara K, Yamada A, Nagayama M, Tabe Y, Ohsaka A. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thromb Res 2014; 133(2): 276-280.
  4. Hu Z, Murakami T, Suzuki K, Tamura H, Kuwahara-Arai K, Iba T, Nagaoka I. Antimicrobial Cathelicidin Peptide LL-37 Inhibits the LPS/ATP-Induced Pyroptosis of Macrophages by Dual Mechanism. PLoS One 2014; 9(1): e85765.
  5. Iba T, Nagaoka I, Yamada A, Nagayama M, Miki T Effect of Hemoperfusion Using Polymyxin B-immobilized Fibers on Acute Lung Injury in a Rat Sepsis Model. Int J Med Sci 2014; 11(3): 255-261.
  6. Iba T, Miki T, Hashiguchi N, Yamada A, Nagaoka I Combination of antithrombin and recombinant thrombomodulin attenuates leukocyte-endothelial interaction and suppresses the increase of intrinsic DAMPs in endotoxemic rats. J Surg Res 2014; 187(2): 581-586.
  7. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation- The View from Japan. J Thromb Haemost 2014; 12(7): 1010-9.
  8. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I. Is the neutrophil a 'prima donna' in the procoagulant process during sepsis? Critical Care 2014; 8(4): 230.
  9. Iba T, Yamada A, Hashiguchi N, Nagaoka I. New therapeutic options for patients with sepsis and disseminated intravascular coagulation. Pol Arch Med Wewn 2014; 124(6): 321-328.
  10. Iba T. The Obstacles That Should be Overcome to Develop New Anticoagulants for Severe Sepsis. Critical Care Medicine 2014; 42(3): e248-249.
  11. Wada H, Okamoto K, Iba T, Kushimoto S, Kawasugi K, Gando S, Madoiwa S, Uchiyama T, Mayumi T, Seki Y. Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Thromb Res 2014; 134(4): 924-925.
  12. Hashiguchi N, Iba T. Is postoperative polymyxin B hemoperfusion for abdominal septic shock really ineffective? Critical Care Medicine 2014; 42(8): e598-599.
  13. Iba T, Saitoh D. Efficacy of antithrombin in preclinical and clinical application for sepsis-associated disseminated intravascular coagulation. J Intensive Care 2014; 2: 66